Seroconversion stages COVID19 into distinct pathophysiological states
Matthew D. Galbraith(University of Colorado Anschutz Medical Campus), Joaquı́n M. Espinosa(University of Colorado Anschutz Medical Campus), Seth Russell(University of Colorado Denver), Tellen D Benett(University of Colorado Anschutz Medical Campus), Ryan M. Baxter(University of Colorado Anschutz Medical Campus), Kelly D. Sullivan(University of Colorado Anschutz Medical Campus), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Kohl T. Kinning(University of Colorado Anschutz Medical Campus), Angelo D’Alessandro(University of Colorado Anschutz Medical Campus), Andrew A. Monte(Washington Poison Center), Jessica R. Shaw(University of Colorado Anschutz Medical Campus), Ross E. Granrath(University of Colorado Anschutz Medical Campus), Keith P. Smith(University of Colorado Anschutz Medical Campus), Kirk C. Hansen(University of Colorado Anschutz Medical Campus), Monika Dzieciątkowska(University of Colorado Anschutz Medical Campus), Tusharkanti Ghosh(Colorado School of Public Health), Elena WY Hsieh(University of Colorado Anschutz Medical Campus), Paula Araya(University of Colorado Anschutz Medical Campus)
Cited by 53
Related Papers
Transcriptional regulation by hypoxia inducible factors
|Critical Reviews in Biochemistry and Molecular Biology|2013|791
COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status
|JCI Insight|2020|600
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
|Cancer Cell|2018|565
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
|Proceedings of the National Academy of Sciences|2018|556